| Autor: |
Affonso de Oliveira JF; Department of NanoEngineering, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92039, United States., Chan SK; Department of NanoEngineering, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92039, United States., Omole AO; Department of NanoEngineering, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92039, United States., Agrawal V; Department of NanoEngineering, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92039, United States., Steinmetz NF; Department of NanoEngineering, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92039, United States.; Center for Nano-ImmunoEngineering, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92039, United States.; Department of Bioengineering, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92039, United States.; Department of Radiology, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92039, United States.; Moores Cancer Center, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92039, United States.; Institute for Materials Discovery and Design, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92039, United States. |
| Abstrakt: |
Cowpea mosaic virus (CPMV) is a nucleoprotein nanoparticle that functions as a highly potent immunomodulator when administered intratumorally and is used as an in situ vaccine. CPMV in situ vaccination remodels the tumor microenvironment and primes a highly potent, systemic, and durable antitumor immune response against the treated and untreated, distant metastatic sites (abscopal effect). Potent efficacy was demonstrated in multiple tumor mouse models and, most importantly, in canine cancer patients with spontaneous tumors. Data indicate that presence of anti-CPMV antibodies are not neutralizing and that in fact opsonization leads to enhanced efficacy. Plant viruses are part of the food chain, but to date, there is no information on human exposure to CPMV. Therefore, patient sera were tested for the presence of immunoglobulins against CPMV, and indeed, >50% of deidentified patient samples tested positive for CPMV antibodies. To get a broader sense of plant virus exposure and immunogenicity in humans, we also tested sera for antibodies against tobacco mosaic virus (>90% patients tested positive), potato virus X (<20% patients tested positive), and cowpea chlorotic mottle virus (no antibodies were detected). Further, patient sera were analyzed for the presence of antibodies against the coliphage Qβ, a platform technology currently undergoing clinical trials for in situ vaccination; we found that 60% of patients present with anti-Qβ antibodies. Thus, data indicate human exposure to CPMV and other plant viruses and phages. Next, we thought to address agronomical safety; i.e., we examined the fate of CPMV after intratumoral treatment and oral gavage (to mimic consumption by food). Because live CPMV is used, an important question is whether there is any evidence of shedding of infectious particles from mice or patients. CPMV is noninfectious toward mammals; however, it is infectious toward plants including black-eyed peas and other legumes. Biodistribution data in tumor-bearing and healthy mice indicate little leaching from tumors and clearance via the reticuloendothelial system followed by biliary excretion. While there was evidence of shedding of RNA in stool, there was no evidence of infectious particles when plants were challenged with stool extracts, thus indicating agronomical safety. Together these data aid the translational development of CPMV as a drug candidate for cancer immunotherapy. |
